In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, BriaCell Therapeutics Corp (NASDAQ: BCTX) closed at $3.42 down -11.40% from its previous closing price of $3.86. In other words, the price has decreased by -$11.40 from its previous closing price. On the day, 0.5 million shares were traded.
Ratios:
For a deeper understanding of BriaCell Therapeutics Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.37. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on February 14, 2022, initiated with a Buy rating and assigned the stock a target price of $25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 14 ’24 when Lustig Marc bought 902,935 shares for $2.21 per share. The transaction valued at 2,000,001 led to the insider holds 2,542,935 shares of the business.
Stock Price History:
Over the past 52 weeks, BCTX has reached a high of $36.60, while it has fallen to a 52-week low of $3.00. The 50-Day Moving Average of the stock is -15.90%, while the 200-Day Moving Average is calculated to be -59.54%.
Shares Statistics:
A total of 5.72M shares are outstanding, with a floating share count of 5.35M. Insiders hold about 6.47% of the company’s shares, while institutions hold 7.63% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
